Ahead of the HDA Business and Leadership Conference, President and CEO John M. Gray was interviewed by Chain Drug Review as part of the publication’s "Annual Report of Drug Wholesalers."
Published in the June 5 issue, Mr. Gray notes that HDA’s primary pharmaceutical distributor members are ensuring the safety and efficiency of the pharmaceutical supply chain like never before, while discussing such policy issues as DSCSA implementation, prescription drug importation proposals, prescription drug abuse and tax issues.
ABOUT THE HEALTHCARE DISTRIBUTION ALLIANCE
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.